Heron Therapeutics Inc
AXD2
Company Profile
Business description
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Contact
100 Regency Forect Drive
Suite 300
CaryNC27518
USAT: +1 858 251-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
122
Stocks News & Analysis
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
stocks
This US AI champion’s stock is too cheap to ignore
Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.
stocks
Why SpaceX is coming to your Super Fund
Most Australians will end up owning SpaceX — whether they like it or not.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,047.30 | 25.90 | -0.29% |
| CAC 40 | 8,489.20 | 21.22 | 0.25% |
| DAX 40 | 25,118.28 | 91.48 | 0.37% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,400.50 | 0.80 | 0.01% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 71,250.06 | 196.57 | 0.28% |
| NZX 50 Index | 13,495.63 | 132.32 | 0.99% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,828.70 | 27.90 | -0.32% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |